All In Biotech

Drug Trial Radar · NCT00486434

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Apr 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,176

Actual

Start

May 2007

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Nordic Bioscience A/SIndustry
Sponsor type
Industry
Collaborators
Novartis
First posted
Jun 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 51 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoarthritis of the knee.

Conditions

  • Osteoarthritis

Interventions

  • SMC021 Oral CalcitoninDrug

    0.8mg SMC021 (Oral Calcitoinin) twice daily

  • SMC021 PlaceboDrug

    Placebo orally, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Joint Space Width (JSW) in the Medial Tibiofemoral Knee Joint in Signal Knee Measured by X-ray After 24 Months.Time frame: Change from baseline to 24 months
  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscore in the Signal KneeTime frame: Change from baseline to 24 months
  3. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Subscore in the Signal Knee.Time frame: Change from baseline to 24 months

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • CCBR Czech

    Pardubice, Czechia

  • CCBR Aalborg

    Aalborg, Denmark

  • CCBR Ballerup

    Ballerup Municipality, Denmark

  • CCBR Vejle

    Vejle, Denmark

  • CCBR Estonia

    Tallinn, Estonia

  • CCBR Hong Kong

    Hong Kong, Hong Kong

  • Centrum Osteoporozy i Chorób Kostno Stawowych, ul. Waryńskiego 6/2

    Bialystok, Poland

  • CCBR Poland

    Warsaw, Poland

  • CCBR Romania

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.